Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
MWN-AI** Summary
Kane Biotech Inc. has announced the publication of a pivotal article featuring its revyve® Antimicrobial Wound Gel in the International Wound Journal. Authored by Dr. Jeyachchandran Visvalingam, along with researchers from the University of Miami, the article highlights the gel's innovative properties and effectiveness. Key findings indicate that the thermo-reversible gel transitions from a liquid to a gel at body temperature and re-liquefies when cooled, facilitating easy removal.
Significantly, revyve has shown impressive antibacterial efficacy against common wound-related pathogens, achieving up to a 99.9999% reduction in bacterial counts within 30 minutes. Furthermore, its sustained in vitro activity lasts for up to seven days, which may decrease the frequency of dressing changes required. Comprehensive safety evaluations, including biocompatibility tests and porcine wound-healing studies, affirm the gel's non-cytotoxicity.
Revyve® is both FDA 510(k) cleared and Health Canada approved, underscoring its regulatory compliance and market readiness. The publication in the International Wound Journal serves not only as validation of the gel's scientific foundation but also enhances Kane Biotech's credibility among clinicians, regulatory bodies, and commercial partners. Interim CEO Dr. Robert Huizinga emphasized the importance of this peer-reviewed acknowledgment, reinforcing Kane Biotech's commitment to developing evidence-based solutions aimed at improving patient outcomes in wound care.
Kane Biotech specializes in creating advanced wound care treatments that address biofilms—a major contributor to antibiotic resistance. Their product lineup includes revyve® Antimicrobial Wound Gel, Wound Gel Spray, and Skin and Wound Cleanser, each designed to transform healing outcomes and combat wound-related infections effectively. For further information, the company encourages interested parties to visit their websites and follow their social media channels.
MWN-AI** Analysis
Kane Biotech Inc. (TSX-V:KNE) has recently announced a significant milestone, with the publication of an article highlighting its revyve® Antimicrobial Wound Gel in the esteemed International Wound Journal. This peer-reviewed endorsement underscores the gel's innovative properties and sets a positive tone for the company's market perception.
The key findings from the article indicate that revyve® not only demonstrates impressive antimicrobial efficacy—showing over 99.99% reduction of bacteria like Staphylococcus aureus and Pseudomonas aeruginosa—but also possesses sustained activity for up to seven days. This extends the potential interval required between dressing changes, which can be a major convenience in clinical settings, enhancing its commercial viability.
The gel's favorable safety profile, validated by biocompatibility testing, is pivotal in mitigating concerns often associated with new medical products. With its U.S. FDA 510(k) clearance and Health Canada approval, Kane Biotech has effectively positioned itself within a competitive landscape that prioritizes rigorous regulatory standards.
Given the backdrop of rising antibiotic resistance and the increasing prevalence of wound-related infections, the market outlook for effective antimicrobial solutions is promising. Kane Biotech's concentrated focus on disrupting biofilms places it at a strategic advantage, targeting a significant healthcare challenge with a differentiated product offering.
Investors should remain cautiously optimistic. While the positive publication and growing recognition in the medical community could influence stock performance favorably, attention must be paid to the company's financial status. Kane Biotech currently relies on equity financing and lacks significant revenue, presenting inherent investment risks. Investors are advised to monitor developments regarding market adoption of revyve®, its operational performance, and any potential partnerships that could accelerate commercial success. Overall, diversifying within biotech investments while keeping an eye on Kane’s innovations could yield beneficial outcomes in the long-run.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve® Antimicrobial wound gel in the International Wound Journal. The article “Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity” is first-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader, and includes authors from the Miller School of Medicine, Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami.
Key messages of the article as it relates to Kane’s revyve wound gel include:
- The thermo-reversible gel shifts from a low viscosity liquid to a form-fitting gel at body temperature, then re-liquefies when cooled for easy, atraumatic removal.
- revyve demonstrated efficacy against a broad range of wound-related pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa, with a 99.99%–99.9999% reduction in bacterial counts within 30 min.
- There was sustained in vitro activity for up to 7 days, potentially reducing the number of dressing changes.
- The safety and non-cytotoxicity of the gel were validated through biocompatibility testing and a porcine wound-healing study.
US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel
The International Wound Journal is a peer-reviewed scientific journal focused on research in wound care and wound healing. It publishes original studies, clinical research, and reviews that advance knowledge in wound prevention, treatment, and management.
The article can be viewed here.
“Having our research published in the International Wound Journal underscores the scientific rigor behind revyve technology and provides independent, peer-reviewed validation of the gel’s safety, in vitro performance and clinical potential,” said Interim CEO, Dr. Robert Huizinga. “Recognition in such a respected global wound-care publication strengthens our credibility with clinicians, regulators and commercial partners, and reinforces our commitment to advancing evidence-based solutions that improve patient outcomes.”
About Kane Biotech Inc. (TSX-V:KNE)
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria. revyve® Antimicrobial Wound Gel, revyve® Antimicrobial Wound Gel Spray and revyve® Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.
Join Kane’s Distribution List & Social Media:
To stay informed on the latest developments, sign up for the Company’s email distribution list HERE.
Follow Kane
Website: kanebiotech.com
LinkedIn: https://www.linkedin.com/company/kanebiotech/
Presentations: https://kanebiotech.com/publications-posters/
| For more information: | |
| Dr. Robert Huizinga Interim CEO Kane Biotech Inc. rhuizinga@kanebiotech.com (780) 970-1100 | Ray Dupuis Chief Financial Officer Kane Biotech Inc. rdupuis@kanebiotech.com (204) 298-2200 |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/32597a8c-e4f5-4846-8ef1-7678003c4724
FAQ**
How does Kane Biotech Inc. KNBIF plan to leverage the recent publication in the International Wound Journal to attract potential investors and partners in the wound care industry?
Considering the significant efficacy demonstrated by revyve in reducing bacterial counts, how does Kane Biotech Inc. KNBIF envision its product positioning in a competitive market?
With the recognition from the International Wound Journal, what strategies will Kane Biotech Inc. KNBIF implement to scale production and distribution of revyve, particularly in North America?
What measures are in place at Kane Biotech Inc. KNBIF to address potential risks outlined regarding financial condition, market acceptance, and technological changes in the wound care sector?
**MWN-AI FAQ is based on asking OpenAI questions about Kane Biotech Inc. (OTC: KNBIF).
NASDAQ: KNBIF
KNBIF Trading
0.0% G/L:
$0.027 Last:
10,000 Volume:
$0.027 Open:
